Arcus Biosciences, Inc. (NYSE: RCUS) discloses planned Rule 144 sale of 55,000 shares

Rhea-AI Filing Summary

Arcus Biosciences, Inc. has a shareholder filing a notice under Rule 144 to sell up to 55,000 shares of common stock through broker E*TRADE Financial, with an aggregate market value of $1,204,500 and an approximate sale date of 12/16/2025 on the NYSE.

The notice states that the securities to be sold were acquired through vesting of restricted stock on 12/15/2025, granted on 3/8/2022, 1/23/2023, 1/23/2024, and 1/23/2025 as compensation for services rendered.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
COMMON	E*TRADE FINANCIAL CORPORATION 3 EDISON DRIVE ALPHARETTA GA 3005	55000	1204500	122856086	12/16/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
COMMON	12/15/2025	Vesting of restricted stock granted 3/8/2022	Arcus Biosciences, Inc.			15031	12/15/2025	Services rendered
COMMON	12/15/2025	Vesting of restricted stock granted 1/23/2023	Arcus Biosciences, Inc.			26425	12/15/2025	Services rendered
COMMON	12/15/2025	Vesting of restricted stock granted 1/23/2024	Arcus Biosciences, Inc.			25000	12/15/2025	Services rendered
COMMON	12/15/2025	Vesting of restricted stock granted 1/23/2025	Arcus Biosciences, Inc.			41250	12/15/2025	Services rendered

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the latest Form 144 filing reveal about Arcus Biosciences (RCUS)?

The Form 144 shows that a shareholder of Arcus Biosciences, Inc. plans to sell up to 55,000 shares of common stock through E*TRADE Financial, with an aggregate market value of $1,204,500, on the NYSE.

How many Arcus Biosciences (RCUS) shares are proposed for sale and what is their value?

The notice covers a proposed sale of 55,000 shares of Arcus Biosciences common stock, with an indicated aggregate market value of $1,204,500.

When and where are the Arcus Biosciences (RCUS) shares expected to be sold?

The approximate date of sale listed is 12/16/2025, and the shares are indicated to be sold on the NYSE.

How were the Arcus Biosciences (RCUS) shares in this Form 144 acquired?

The securities were acquired through vesting of restricted stock on 12/15/2025, from grants dated 3/8/2022, 1/23/2023, 1/23/2024, and 1/23/2025, described as consideration for services rendered.

Who is the broker handling the planned sale of RCUS shares in the Form 144?

The filing lists E*TRADE Financial Corporation, located at 3 Edison Drive, Alpharetta, GA 3005, as the broker for the proposed sale of Arcus Biosciences common stock.

What type of Arcus Biosciences (RCUS) security is being sold under this Form 144?

The filing specifies the COMMON stock class of Arcus Biosciences, Inc. as the security to be sold.